XTAE
NXGN
Market cap1mUSD
Apr 03, Last price
61.30ILS
1D
0.49%
1Q
-5.84%
Jan 2017
-46.79%
Name
Nextgen Biomed Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-24.18%
Rev. gr., 5y
%
Revenues
0k
Net income
-14m
L+65.56%
CFO
-4m
L+60.01%
Profile
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 5,248 | 2,493 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,248) | (2,493) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 799 | ||||||||
Tax Rate | |||||||||
NOPAT | (5,248) | (3,292) | |||||||
Net income | (14,192) 65.56% | (8,572) 236.16% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,379 | ||||||||
Net debt | (145) | (5,240) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (4,405) | (2,753) | |||||||
CAPEX | (33) | ||||||||
Cash from investing activities | (786) | (4,000) | |||||||
Cash from financing activities | |||||||||
FCF | (4,269) | (3,285) | |||||||
| Balance | |||||||||
Cash | 145 | 5,240 | |||||||
Long term investments | |||||||||
Excess cash | 145 | 5,240 | |||||||
Stockholders' equity | (66,169) | (51,969) | |||||||
Invested Capital | 65,190 | 65,598 | |||||||
ROIC | |||||||||
ROCE | 536.06% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 7,263 | 43,349 | |||||||
Price | 1.27 -66.19% | 3.76 -55.05% | |||||||
Market cap | 9,239 -94.33% | 163,077 -50.89% | |||||||
EV | 8,975 | 157,726 | |||||||
EBITDA | (5,246) | (2,486) | |||||||
EV/EBITDA | |||||||||
Interest | 64 | ||||||||
Interest/NOPBT | |||||||||